基本信息
浏览量:634
职业迁徙
个人简介
The research of Robert B. Jenkins, M.D., Ph.D., is focused on cancer genetics, particularly elucidation of the genetic events important for cancer initiation and progression. His primary interest is in the genetics of gliomas, where both his basic genetic studies and clinical translation activities have had a major impact on neuro-oncology.
Dr. Jenkins' lab has worked in several areas of neuro-oncology. For example, the lab developed carrier peptides to deliver proteins and small molecules across the blood-brain barrier, technology which has been licensed by several drug companies and is showing evidence of success for the treatment of neurological disorders.
The lab was also involved in the development of the Food and Drug Administration (FDA)-approved dual-probe fluorescence in situ hybridization (FISH) test that is used to stratify patients for the treatment with HER2-targeted therapies.
Dr. Jenkins' team has developed an expression profiling test that predicts which men with prostate cancer are likely to develop clinical progression. This test is nearing submission for FDA approval.
Dr. Jenkins has also been involved in the development of several other genetic tests, including an FDA-approved urine screening test for bladder cancer (for which he holds the patent) as well as multiple FISH and array comparative genomic hybridization tests.
Dr. Jenkins' lab has worked in several areas of neuro-oncology. For example, the lab developed carrier peptides to deliver proteins and small molecules across the blood-brain barrier, technology which has been licensed by several drug companies and is showing evidence of success for the treatment of neurological disorders.
The lab was also involved in the development of the Food and Drug Administration (FDA)-approved dual-probe fluorescence in situ hybridization (FISH) test that is used to stratify patients for the treatment with HER2-targeted therapies.
Dr. Jenkins' team has developed an expression profiling test that predicts which men with prostate cancer are likely to develop clinical progression. This test is nearing submission for FDA approval.
Dr. Jenkins has also been involved in the development of several other genetic tests, including an FDA-approved urine screening test for bladder cancer (for which he holds the patent) as well as multiple FISH and array comparative genomic hybridization tests.
研究兴趣
论文共 601 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
medRxiv : the preprint server for health sciences (2024)
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
openalex(2023)
crossref(2023)
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn